Author:
Chanan-Khan Asher,Miller Kena C.,Lawrence David,Padmanabhan Swaminathan,Miller Austin,Hernandez-Illatazurri Francisco,Czuczman Myron S.,Wallace Paul K.,Zeldis Jerome B.,Lee Kelvin
Reference15 articles.
1. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma;Richardson;Blood.,2002
2. Efficacy of lenalidomide in myelodysplastic syndromes;List;N Engl J Med.,2005
3. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications;Chang;Blood.,2006
4. CC-5013 (Celgene);Mitsiades;Curr Opin Investig Drugs.,2004
5. Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial;Chanan-Khan;Leuk Lymphoma.,2007
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献